Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Botanix Pharmaceuticals Limited ( (AU:BOT) ) just unveiled an update.
Botanix Pharmaceuticals has relocated its registered office, principal place of business and postal address to Level 23, Tower 5, Collins Square, 727 Collins Street, Melbourne, Victoria, effective immediately. The move centralises the company’s corporate presence in Australia while leaving all other corporate details unchanged, signalling an administrative shift rather than an operational change to its dermatology portfolio.
The company continues to focus on commercialising Sofdra, its FDA‑approved treatment for primary axillary hyperhidrosis, which is positioned as a novel and effective option in a market where patients have historically had few choices. This approval underpins Botanix’s growth strategy in medical dermatology and reinforces its positioning in a specialised niche of the global pharmaceutical industry.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$0.14 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a commercial dermatology company listed on the ASX and based in Philadelphia and Phoenix. The company has secured U.S. FDA approval for Sofdra, a novel treatment for primary axillary hyperhidrosis and the first new chemical entity cleared for this condition, targeting patients with limited existing therapeutic options.
Average Trading Volume: 23,432,036
Technical Sentiment Signal: Sell
Current Market Cap: A$70.73M
For a thorough assessment of BOT stock, go to TipRanks’ Stock Analysis page.